Zura Bio Limited
ZURAHealthcare|Biotechnology|US
$4.09
+0.37 (+9.95%)
DCF Value
$1.15
Tangible Book / Share
$1.39
Cash / Share
$1.47
Financials
Financial Snapshot
Market Cap
$394.0M
Enterprise Value
$206.3M
Revenue (TTM)
$0.00
Net Income (TTM)
-$93.5M
Cash & Investments
$187.7M
Net Cash
$187.7M
Free Cash Flow (TTM)
-$81.7M
Operating CF (TTM)
-$81.6M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$187.7M
Quarterly Burn
$20.4M
Monthly Burn
$6.8M
Est. Runway
~9.2 quarters
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Investments | — | $1.6M | $99.8M | $176.5M | $109.4M | $187.7M | |
| Operating Cash Flow | -$1.1M | -$1.2M | -$15.1M | -$28.1M | -$64.8M | -$81.6M | |
| Free Cash Flow | -$1.1M | -$13.2M | -$23.1M | -$28.2M | -$64.9M | -$81.7M | |
| Capital Expenditure | -$4.00 | -$12.0M | -$8.0M | -$75.0K | -$113.0K | -$90.0K | |
| Financing Cash Flow | $141.2M | $14.8M | $121.3M | $109.8M | -$2.2M | $130.3M |
R&D Spending
R&D (TTM)
$65.9M
R&D Intensity
—
R&D Growth vs Prior
+56.6%
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $0.00 | $23.7M | $44.0M | $24.4M | $42.1M | $65.9M | |
| SG&A | $1.1M | $3.5M | $18.6M | $30.8M | $33.2M | $36.1M |
Income Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $0.00 | $23.7M | $44.0M | $24.4M | $42.1M | $65.9M | |
| SG&A | $1.1M | $3.5M | $18.6M | $30.8M | $33.2M | $36.1M | |
| Operating Income | -$1.1M | -$27.2M | -$62.6M | -$55.2M | -$75.2M | -$102.0M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $8.4M | -$27.3M | -$60.6M | -$52.4M | -$68.7M | -$94.8M | |
| Net Income | $8.4M | -$25.7M | -$60.4M | -$52.4M | -$68.7M | -$93.5M | |
| EPS (Diluted) | 0.40 | -1.88 | -2.09 | -0.60 | -1.06 | -1.12 | |
| EBITDA | $8.4M | -$27.3M | -$60.6M | -$52.4M | -$68.6M | -$94.8M | |
| Shares Out. (M) | 17.25 | 17.25 | 33.06 | 75.07 | 94.16 | 127.71 |
Balance Sheet
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | — | $1.6M | $99.8M | $176.5M | $109.4M | $187.7M | |
| Short-Term Investments | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | — | $1.8M | $100.8M | $178.7M | $112.3M | $191.6M | |
| Total Assets | — | $5.3M | $100.8M | $179.5M | $113.9M | $194.6M | |
| Total Current Liabilities | — | $14.8M | $20.3M | $19.5M | $12.4M | $17.0M | |
| Long-Term Debt | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | — | $27.3M | $21.3M | $19.5M | $12.4M | $17.0M | |
| Stockholders' Equity | — | -$32.1M | $59.3M | $146.8M | $101.5M | $177.7M | |
| Retained Earnings | — | -$32.1M | -$103.5M | -$155.9M | -$224.5M | -$300.9M |
Cash Flow Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.1M | -$1.2M | -$15.1M | -$28.1M | -$64.8M | -$81.6M | |
| Capital Expenditure | -$4.00 | -$12.0M | -$8.0M | -$75.0K | -$113.0K | -$90.0K | |
| Free Cash Flow | -$1.1M | -$13.2M | -$23.1M | -$28.2M | -$64.9M | -$81.7M | |
| Investing Cash Flow | -$139.4M | -$12.0M | -$8.0M | -$5.1M | -$113.0K | -$90.0K | |
| Financing Cash Flow | $141.2M | $14.8M | $121.3M | $109.8M | -$2.2M | $130.3M | |
| Issuance of Stock | $140.8M | $0.00 | $116.4M | $60.8M | $5.2M | $137.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$117.4K | $7.6M | -$10.0M | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $334.0K | $9.7M | $16.8M | $12.3M | $17.4M | |
| Net Change in Cash | $729.2K | $1.6M | $98.2M | $76.7M | -$67.1M | $48.6M |
Dilution Tracker
Shares outstanding grew 445.9% over 5 years — significant dilution
Shares Outstanding
96M
5-Year Share Growth
+445.9%
Stock Issuance (TTM)
$137.8M
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 17.25 | 17.25 | 33.06 | 75.07 | 94.16 | 127.71 | |
| Change vs Prior % | — | 0.0% | 91.7% | 127.0% | 25.4% | 35.6% | |
| Stock Issuance | $140.8M | $0.00 | $116.4M | $60.8M | $5.2M | $137.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $334.0K | $9.7M | $16.8M | $12.3M | $17.4M |
Margins & Profitability
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| ROE % | 0.0% | 80.3% | -101.7% | -35.7% | -67.6% | -54.0% | |
| ROA % | 0.0% | -489.1% | -59.9% | -29.2% | -60.2% | -48.1% | |
| ROIC % | 0.0% | 1509.0% | -77.8% | -34.5% | -74.1% | -56.6% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -2387.4% | -130.6% | 11.9% | -36.3% | |
| Net Income | 0.0% | -405.8% | -134.5% | 13.2% | -31.0% | |
| EPS (Diluted) | 0.0% | -570.0% | -11.2% | 71.3% | -76.7% | |
| Operating Cash Flow | 0.0% | -9.5% | -1152.4% | -86.5% | -130.9% | |
| Free Cash Flow | 0.0% | -1102.2% | -74.6% | -22.1% | -130.6% | |
| R&D Expense | 0.0% | 0.0% | 85.7% | -44.5% | 72.5% | |
| SG&A Expense | 0.0% | 218.0% | 436.7% | 65.2% | 7.7% | |
| Total Assets | 0.0% | 0.0% | 1816.4% | 78.0% | -36.5% | |
| Book Value / Share | 0.0% | 0.0% | 288.2% | -11.4% | -49.4% | |
| Debt | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | 91.7% | 127.0% | 25.4% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B2.94
10Y Low / Med / High1.28 / 2.60 / 4.86
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1.15
Tangible Book / Share
$1.39
Net Current Assets / Share
$1.81
Graham Net-Net
$1.34
Cash / Share
$1.47
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| P/E Ratio | 18.10 | -3.85 | -2.23 | -4.17 | -4.94 | -3.65 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 0.00 | -3.90 | 2.60 | 1.28 | 4.86 | 2.94 | |
| EV/EBITDA | 0.00 | -4.80 | -0.90 | -0.21 | -5.60 | -2.18 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
11.23
Safe
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $8.3M | $9.4M | $6.3M |
| Net Income | -$76.0M | -$63.9M | -$86.5M |
| EPS | $-0.82 | $-0.76 | $-0.88 |
| # Analysts (EPS) | 5 | 5 | 7 |